The estimated 5-year risk for the renal outcome was 2.4 vs 2.1% for people taking GLP-1 receptor agonists or SGLT-2 inhibitors vs those taking DPP-4 inhibitors. HealthDay News — For adults with type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results